Select publications

Cassidy J et al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): Efficacy results of a phase III trial. Presentation. ASCO 2004;Abstract 3509.

Crane CH, Sargent DJ. Substitution of oral fluoropyrimidines for infusional fluorouracil with radiotherapy: How much data do we need? J Clin Oncol 2004;22(15):2978-81. No abstract available

Gerard J et al. Preoperative (preop) radiotherapy (RT) + 5 FU/folinic acid (FA) in T3-4 rectal cancers: Results of the FFCD 9203 randomized trial. Presentation. ASCO 2005;Abstract 3504.

Hofheinz RD et al. Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 2005;23(7):1350-7. Abstract

Nygren P et al. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report. Acta Oncol 2005;44(3):203-17. Abstract

O’Connell MJ et al. Update on design of the National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 2005;23(4):933-4. No abstract available

Rodel C, Sauer R. Neoadjuvant radiotherapy and radiochemotherapy for rectal cancer. Recent Results Cancer Res 2005;165:221-30. Abstract

Willett CG et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004a;10(2):145-7. Abstract

Willett CG et al. Phase I study of neoadjuvant bevacizumab, 5-fluorouracil, and radiation therapy followed by surgery for patients with primary rectal cancer. Proc ASCO 2004b;Abstract 3589.